This year’s Multidisciplinary Head and Neck Cancers Symposium was dedicated to the theme of “Advancing Patient-centered Care through Innovative Team Science.” Held on February 19-21 in Palm Desert, California, the meeting brought together diverse voices across oncology disciplines. Dynamic sessions, plenaries, and poster presentations fostered conversations that navigated the complexity of H&N cancers with an integrated, collaborative mindset.
Keynote speakers included Sana Karam, MD, PhD, who explored key studies in neoadjuvant and adjuvant immunotherapy, along with David Sher, MD, MPH, FASTRO, who provided a sweeping overview of updates on clinical trial data, examining a decreased elective radiation dose and volume.
This meeting equipped multidisciplinary providers to continue to deliver care that is not only cutting-edge, but deeply patient-centered. Each morning began with a patient testimonial, grounding all attendees to the shared mission of advancing treatments to create better outcomes and experiences for patients. Access to this meeting and all of these great learnings continue to be available onDemand to meeting attendees, but if you weren’t able to attend, you can purchase the onDemand Meeting and earn up to 18 AMA PRA Category 1 Credit™.
Explore these articles from the meeting’s Daily News for expert analysis on presented research:
The Quarterback De-Escalation Trials: Sequential Studies of Induction Chemotherapy and Reduced Dose Chemoradiation for HPV Positive Oropharynx Cancer
By Sung Jun Ma, MD, James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center
Early Results of a Multisite Phase II Study of ctDNA-Guided Adjuvant Radiation for Patients with HPV-Related Oropharyngeal Cancer
By Sung Jun Ma, MD, James Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center
Surgical outcomes in KEYNOTE-689: Neoadjuvant and adjuvant pembrolizumab (pembro) in resectable locally advanced head and neck squamous cell carcinoma
By Leah D’Souza, MD, MSc, UK Markey Cancer Center, and Kelly C. Ho, MD, Chicago Medical School at Rosalind Franklin University
Clinical and Patient-Reported Outcomes in C-POST: Phase 3 Trial of Adjuvant Cemiplimab vs. Placebo for High-Risk Cutaneous Squamous Cell Carcinoma
By Ying Hitchcock, MD, FASTRO, Huntsman Cancer Hospital, University of Utah
An Important First Look at Weekly vs. Every Three Week Cisplatin Dosing in p16-Positive Head and Neck Cancer
By Christopher Wilke, MD, PhD, and Yvonne Mowery, MD, PhD, University of Pittsburgh
Plus, these additional resources from the meeting:
- Access the Symposium onDemand.
- Dive into the meeting’s Virtual Poster Library.
- Read the meeting’s Scientific Abstracts. In addition, abstract reviews are available in the online exclusives.
Blog commenting guidelines
- Commenters are required to identify themselves by name. Email verification is required for first time commenters.
- Comments are subject to review and should focus on the content of the blog post or other posted comments. Comments that are commercial or promotional in nature, are not relevant to the blog for which they have been submitted or are otherwise inappropriate will not be posted.
- All defamatory, abusive, harassing, profane, threatening, offensive, pornographic, obscene or illegal materials are strictly prohibited.
- Providing any non-public information about ASTRO or any other company or persons without authorization is prohibited.
- To preserve a climate that encourages both civil and fruitful dialogue, ASTRO reserves the right, in its sole discretion, to delete posts or ban users who violate these rules.
